Identification of Anti-citrullinated Osteopontin Antibodies and Increased Inflammatory Response by Enhancement of Osteopontin Binding to Fibroblast-like Synoviocytes in Rheumatoid Arthritis

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2023 Feb 22

PMID 36804906

Authors

Akio Umemoto

Takeshi Kuwada

Koichi Murata

Masahiro Shiokawa

Sakiko Ota

Yoshiki Murotani

Akihiro Itamoto

Kohei Nishitani

Hiroyuki Yoshitomi

Takayuki Fujii

Akira Onishi

Hideo Onizawa

Kosaku Murakami

Masao Tanaka

Hiromu Ito

Hiroshi Seno

Akio Morinobu

Shuichi Matsuda

Affiliations

Soon will be listed here.

Abstract

Background: Anti-citrullinated protein/peptide antibodies (ACPAs) are present in patients at onset and have important pathogenic roles during the course of rheumatoid arthritis (RA). The characteristics of several molecules recognized by ACPA have been studied in RA, but the positivity rate of autoantibodies against each antigen is not high, and the pathogenic mechanism of each antibody is not fully understood. We investigated the role of anti-citrullinated osteopontin (anti-cit-OPN) antibodies in RA pathogenesis.

Methods: Enzyme-linked immunosorbent assays on RA patients' sera were used to detect autoantibodies against OPN. Fibroblast-like synoviocytes (FLS) isolated from RA patients were used to test the binding activity and inflammatory response of OPN mediated by anti-cit-OPN antibodies, and their effect was tested using an inflammatory arthritis mouse model immunized with cit-OPN. Anti-cit-OPN antibody positivity and clinical characteristics were investigated in the patients as well.

Results: Using sera from 224 RA patients, anti-cit-OPN antibodies were positive in approximately 44% of RA patients, while approximately 78% of patients were positive for the cyclic citrullinated peptide (CCP2) assay. IgG from patients with anti-cit-OPN antibody increased the binding activity of OPN to FLSs, which further increased matrix metalloproteinase and interleukin-6 production in TNF-stimulated FLSs. Mice immunized with cit-OPN antibodies experienced severe arthritis. Anti-cit-OPN antibodies in RA patients decreased the drug survival rate of tumor necrosis factor (TNF) inhibitors, while it did not decrease that of CTLA4-Ig.

Conclusions: Anti-cit-OPN antibodies were detected in patients with RA. IgG from patients with anti-cit-OPN antibodies aggravated RA, and anti-cit-OPN antibody was a marker of reduced the survival rate of TNF inhibitors in RA patients.

Citing Articles

Energy landscape analysis and time-series clustering analysis of patient state multistability related to rheumatoid arthritis drug treatment: The KURAMA cohort study.

Yamamoto K, Sakaguchi M, Onishi A, Yokoyama S, Matsui Y, Yamamoto W PLoS One. 2024; 19(5):e0302308.

PMID: 38709812 PMC: 11073743. DOI: 10.1371/journal.pone.0302308.

Immunoregulatory Roles of Osteopontin in Diseases.

Wang L, Niu X Nutrients. 2024; 16(2).

PMID: 38276550 PMC: 10819284. DOI: 10.3390/nu16020312.

Non-mutational neoantigens in disease.

Stern L, Clement C, Galluzzi L, Santambrogio L Nat Immunol. 2024; 25(1):29-40.

PMID: 38168954 PMC: 11075006. DOI: 10.1038/s41590-023-01664-1.

Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.

Qiu Y, Feng X, Liu C, Shi Y, Xu L, You H Arthritis Res Ther. 2024; 26(1):9.

PMID: 38167532 PMC: 10759429. DOI: 10.1186/s13075-023-03243-z.

References

Alivernini S, MacDonald L, Elmesmari A, Finlay S, Tolusso B, Gigante M . Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat Med. 2020; 26(8):1295-1306. DOI: 10.1038/s41591-020-0939-8. View

Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M . Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010; 233(1):34-54. DOI: 10.1111/j.0105-2896.2009.00850.x. View

Smolen J, Aletaha D, McInnes I . Rheumatoid arthritis. Lancet. 2016; 388(10055):2023-2038. DOI: 10.1016/S0140-6736(16)30173-8. View

Shimizu M, Kondo Y, Tanimura R, Furuyama K, Yokosawa M, Asashima H . T-bet represses collagen-induced arthritis by suppressing Th17 lineage commitment through inhibition of RORγt expression and function. Sci Rep. 2021; 11(1):17357. PMC: 8405656. DOI: 10.1038/s41598-021-96699-5. View

Sun M, Rethi B, Krishnamurthy A, Joshua V, Circiumaru A, Hensvold A . Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts. Ann Rheum Dis. 2019; 78(12):1621-1631. PMC: 6900251. DOI: 10.1136/annrheumdis-2018-214967. View

Take Y, Nakata K, Hashimoto J, Tsuboi H, Nishimoto N, Ochi T . Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6. Arthritis Rheum. 2009; 60(12):3591-601. DOI: 10.1002/art.25020. View

Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S . Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum. 2008; 58(7):2041-52. DOI: 10.1002/art.23490. View

Si J, Wang C, Zhang D, Wang B, Zhou Y . Osteopontin in Bone Metabolism and Bone Diseases. Med Sci Monit. 2020; 26:e919159. PMC: 7003659. DOI: 10.12659/MSM.919159. View

Schwenzer A, Jiang X, Mikuls T, Payne J, Sayles H, Quirke A . Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis. Ann Rheum Dis. 2015; 75(10):1876-83. PMC: 5036245. DOI: 10.1136/annrheumdis-2015-208495. View

10.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

11.

Sakata M, Tsuruha J, Masuko-Hongo K, Nakamura H, Matsui T, Sudo A . Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2001; 28(7):1492-5. View

12.

Scherer H, Haupl T, Burmester G . The etiology of rheumatoid arthritis. J Autoimmun. 2020; 110:102400. DOI: 10.1016/j.jaut.2019.102400. View

13.

Bonifacio A, Alunno A, La Paglia G, Valentini E, Leone M, Bartoloni E . Novel autoantibodies in rheumatoid arthritis. Reumatismo. 2019; 71(1):1-12. DOI: 10.4081/reumatismo.2019.1102. View

14.

Murata K, Ito H, Hashimoto M, Murakami K, Watanabe R, Tanaka M . Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort. Arthritis Res Ther. 2020; 22(1):268. PMC: 7664066. DOI: 10.1186/s13075-020-02366-x. View

15.

Murata K, Fang C, Terao C, Giannopoulou E, Lee Y, Lee M . Hypoxia-Sensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis. Immunity. 2017; 47(1):66-79.e5. PMC: 5568808. DOI: 10.1016/j.immuni.2017.06.018. View

16.

Doi K, Murata K, Ito S, Suzuki A, Terao C, Ishie S . Role of Lysine-Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia-Inducible Factor 1α and E2F1. Arthritis Rheumatol. 2022; 74(6):948-960. PMC: 9156537. DOI: 10.1002/art.42074. View

17.

Korganow A, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T . From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999; 10(4):451-61. DOI: 10.1016/s1074-7613(00)80045-x. View

18.

Shelef M, Bennin D, Mosher D, Huttenlocher A . Citrullination of fibronectin modulates synovial fibroblast behavior. Arthritis Res Ther. 2012; 14(6):R240. PMC: 3674601. DOI: 10.1186/ar4083. View

19.

Martin-Mola E, Balsa A, Garcia-Vicuna R, Gomez-Reino J, Gonzalez-Gay M, Sanmarti R . Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016; 36(8):1043-63. DOI: 10.1007/s00296-016-3506-3. View

20.

van Beers J, Willemze A, Jansen J, Engbers G, Salden M, Raats J . ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther. 2013; 15(5):R140. PMC: 3978944. DOI: 10.1186/ar4322. View